Vivesto AB (OSTO:VIVE) Other Current Payables: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:VIVE Vivesto AB OSTO:VIVE
26 GF Score
Price kr8.44
! 1 Warning Sign
View Full Analysis

What is Vivesto AB Other Current Payables?

Vivesto AB OSTO:VIVE -0.12% 26 Other Current Payables is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:VIVE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Vivesto AB's Other Current Payables for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Vivesto AB's quarterly Other Current Payables increased from Sep. 2025 (kr0.00 Mil) to Dec. 2025 (kr0.26 Mil) but then declined from Dec. 2025 (kr0.26 Mil) to Mar. 2026 (kr0.00 Mil).

Vivesto AB's annual Other Current Payables stayed the same from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr0.00 Mil) but then increased from Dec. 2024 (kr0.00 Mil) to Dec. 2025 (kr0.26 Mil).

Vivesto AB Other Current Payables Related Terms

Vivesto AB Other Current Payables Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Other Current Payables Chart

Vivesto AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.26

Vivesto AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.26 0.00
OSTO:VIVE
26GF Score
Vivesto AB OSTO:VIVE
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivesto AB Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of kr0.00 Mil mean?
Vivesto AB (OSTO:VIVE) has a Other Current Payables of kr0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vivesto AB and its competitors.
Is Vivesto AB's Other Current Payables too high?
Vivesto AB's current Other Current Payables is kr0.00 Mil. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Other Current Payables compare to ZTS and UTHR?
Vivesto AB's Other Current Payables of kr0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Vivesto AB and its competitors. Vivesto AB's current Other Current Payables is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current Other Current Payables of kr0.00 Mil. The current Other Current Payables is kr0.00 Mil. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current Other Current Payables is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Other Exchanges OMA:Germany
Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score

Get the complete analysis for OSTO:VIVE

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.44
Price